PharmaCyte Biotech (OTCMKTS:PMCB – Get Rating) and Cortexyme (NASDAQ:CRTX – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.

PharmaCyte Biotech has a beta of -0.03, meaning that its stock price is 103% less volatile than the S&P 500. Comparatively, Cortexyme has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500.

33.2% of PharmaCyte Biotech shares are owned by institutional investors. Comparatively, 63.2% of Cortexyme shares are owned by institutional investors. 5.6% of PharmaCyte Biotech shares are owned by company insiders. Comparatively, 27.9% of Cortexyme shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

This table compares PharmaCyte Biotech and Cortexyme’s top-line revenue, earnings per share and valuation.

PharmaCyte Biotech is trading at a lower price-to-earnings ratio than Cortexyme, indicating that it is currently the more affordable of the two stocks.

This is a summary of current recommendations and price targets for PharmaCyte Biotech and Cortexyme, as reported by MarketBeat.com.

This table compares PharmaCyte Biotech and Cortexyme’s net margins, return on equity and return on assets.

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.